Another Covid-19 Vaccine In China Will Enter Clinical Trials: Inactivated Vaccine

On April 13th, it was noted that the Phase I / II clinical trial of a new coronavirus (COVID-19) inactivated vaccine (Vero cell) developed by Sinopharm China Wuhan Bioproducts Research Institute Co., Ltd. was registered in the China Clinical Trial Registration Center It is in the pre-registration state of “passed review”.
According to public information, this is the second new coronavirus vaccine registered in clinical trials in China after the team of Chen Wei, academician of the Chinese Academy of Engineering and researcher of the Academy of Military Medical Sciences, Academy of Military Sciences.
With the severe situation of the international epidemic situation, the development of the COVID-19 virus vaccine has become more urgent. According to the previous press conference of the Joint Defense and Joint Control Mechanism of the State Council of China, after the outbreak, China chose five technical routes to accelerate the development of the COVID-19 virus vaccine, including inactivated vaccine, genetically engineered subunit vaccine, adenovirus vector vaccine, Attenuated influenza virus vector vaccine and nucleic acid vaccine. It can be seen that the five technical routes adopted by China cover the major types of COVID-19 virus vaccines under study worldwide.
The clinical trial registration information shows that the research and development registration title of the Wuhan Institute of Biological Products Co., Ltd. is “New Coronavirus (COVID-19) Inactivated Vaccine (Vero Cell) Randomized, Double-blind, Placebo Parallel Control Phase I / II Clinical “Trial”; the official scientific name of the research project is: Randomized, double-blind placebo parallel control I / Ⅱ to evaluate the safety and immunogenicity of the new inactivated coronavirus vaccine (Vero cells) in healthy people aged 6 years and above Phase clinical trials.
At present, the clinical study has been approved by the ethics committee and is in the pre-registration state of “passed review”.
“China Biotech has achieved important stage results in the research and development of inactivated COVID-19 vaccines, and is expected to provide a” killer “for winning the decisive battle against the epidemic.” At the press conference held by the joint defense and control mechanism of the State Council on the afternoon of April 8 , Said Liu Jingzhen, chairman of Sinopharm Group.
According to the surging news reported on April 12, Academician Zhong Nanshan once said at a meeting with South Korean epidemic prevention experts that five vaccines in China are being developed at the same time, and adenovirus vector vaccines and fully inactivated vaccines are currently being carried out faster. The first phase of clinical trials of adenovirus vaccines has begun, and clinical trials of fully inactivated vaccines will soon begin. “We need to observe for a period of time after the clinical trial, usually one to two years, but it may also be listed in advance due to the development of the disease.”
On the evening of the previous day, on the evening of the 11th, organized by the People’s Daily and other media, “COVID-19 Anti-epidemic Cloud Frontier Cloud Seminar”, China Bio Chairman Yang Xiaoming introduced The vaccine is progressing faster and the technology is more mature. “I believe that the domestic COVID-19 vaccine will meet you soon.”
According to previous statistics of the World Health Organization (WHO), as of March 21, a total of 51 candidate vaccines are under development worldwide, and two of them have entered the clinical trial stage. One is the American biotechnology company Moderna announced on March 16 local time that the mRNA vaccine developed by the company began human trials.
The other is that the research team led by Chen Wei, academician of the Chinese Academy of Engineering and researcher of the Academy of Military Medical Sciences of the Academy of Military Sciences, adopted the adenoviral vector method, and the recombinant new coronavirus (2019-COV) vaccine developed through the clinical research registration review on March 16 Evaluation; at 20:18 on the same day, approved to enter the clinical trial. As of now, the team of Chen Wei is recruiting volunteers for Phase II clinical trials for clinical trials.
In other words, the new coronavirus (COVID-19) inactivated vaccine developed by Sinopharm Group China Bio-Wuhan Biological Products Research Institute Co., Ltd. may be the third COVID-19 virus vaccine in clinical trials in the world.
According to the previous press conference of the Joint Defense and Joint Control Mechanism of the State Council of China, after the outbreak, China chose five technical routes to accelerate the development of the COVID-19 virus vaccine, including inactivated vaccine, genetically engineered subunit vaccine, adenovirus vector vaccine, Attenuated influenza virus vector vaccine and nucleic acid vaccine.
So how long will it take to develop an approved COVID-19 virus vaccine that can be used on a large scale? The Director General of the World Health Organization Tan Desai said at a regular press conference that the development of the COVID-19 vaccine will take at least 12 to 18 months. Anthony Fudge, director of the National Institute of Allergy and Infectious Diseases, has previously stated that even if the initial safety test of the vaccine is going well, it will take a year to a year and a half from its large-scale application.